梯瓦制药 TEVA 深沪

等待开盘 08-28 09:30:00 美东时间

18.05

-0.100

-0.55%

华盛通

立即下载

最高18.26
今开18.22
成交量 858.21万股
最低 17.96
昨收 18.15
总市值 207.03亿
52周最高 22.80
市盈率 ^静 --
换手率 0.75%
52周最低 12.465
委比 94.33%
总股本 11.47亿
历史最高 69.8535
量比 0.71
振幅 1.65%
历史最低 6.07
每手 1
风险率 1.88%

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

美诺华中报业绩会

（来源：纪要大本营）美诺华2025年中报业绩电话交流会　　吴晗国泰海通证券好的，尊敬的各位线上投资人、分析师，大家下午好。欢迎大家参加美诺华2025年...

08-27 22:17
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Tevogen's institutional ownership of common stock rose 24% in Q2 2025, following a 60% increase in Q1. Morgan Stanley and BlackRock accounted for 80% of the growth, with institutional holders increasing from 51 to 55, and 72% maintaining or boosting their positions.

08-25 19:10
Vanda asks FDA's Makary to review approval of Hetlioz generics

Vanda Pharmaceuticals (NASDAQ:VNDA) has formally asked U.S. FDA Commissioner Marty Makary to review the recently retired director of the Center for Drug Evaluation and Research's decision to uphold th...

08-22 05:35
期权扫描 | Palantir股价遭重挫！获一CALL单抄底看涨至162.5美元；Rigetti期权成交放量超800%

Palantir股价遭重挫！获一CALL单抄底看涨至162.5美元；英伟达看涨期权成交占比超65%；量子计算概念股Rigetti期权成交放量超800%>>

08-20 15:46
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Tevogen Bio Holdings Inc. reported improved operational efficiency with a Q2 2025 loss of $5.4 million, down from $8.6 million in Q2 2024. The company is focusing on capital efficiency, infrastructure development, and advancing AI capabilities. Anticipated revenue is expected by late 2026, while efforts are underway to address limited tradable float and enhance production control through a new GMP manufacturing facility.

08-19 16:10
Druckenmiller's Duquesne adds Warner Bros., exits BridgeBio among Q2 trades

Stanley Druckenmiller's Duquesne Family Office took new stakes in Warner Brothers Discovery (NASDAQ:WBD) and Brazilian digital bank Nu Holdings (NYSE:NU), while it dumped its holdings in Bridge Bio Ph...

08-19 05:35
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- In a statement from Ryan Saadi, M.D., M.P.H., Founder and CEO of Tevogen Bio Holdings Inc. (Nasdaq: TVGN), the Company highlighted its asset-rich status and plans to share a comprehensive inventory of its wholly owned internally developed assets, including intellectual property, drug development platforms, and proprietary AI technology. With 74% insider ownership, Tevogen remains committed to advanc...

08-14 19:55
Puretech Health Launches Celea Therapeutics To Transform Treatment Of Respiratory Diseases

Former Teva North America CEO Sven Dethlefs, PhD, to lead CeleaPureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of

08-12 19:15
SA Asks: How could higher India tariffs impact drug stocks?

India is a major supplier of prescription drugs, over-the-counter medications, and pharmaceutical ingredients to the United States. Recently, President Trump announced he intends to impose a 25% tari...

08-08 01:00
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

The FDA has approved AJOVY for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh at least 45 kg. As the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and adult migraine prevention, AJOVY offers a monthly treatment option that can be administered in-office or at home, addressing a significant gap in care for younger patients and reduc...

08-06 11:00

派息除权日	每股总股息	派息日期
2017-11-27	0.07	2017-12-12
2017-08-25	0.07	2017-09-14
2017-06-01	0.29	2017-06-22
2017-02-28	0.29	2017-03-20
2016-12-01	0.29	2016-12-20
2016-08-18	0.29	2016-09-08
2016-05-20	0.29	2016-06-07
2016-02-25	0.29	2016-03-14
2015-11-13	0.29	2015-12-03
2015-08-18	0.29	2015-09-03
2015-05-15	0.29	2015-06-04
2015-02-17	0.29	2015-03-03
2014-11-13	0.27	2014-12-02
2014-08-19	0.29	2014-09-04
2014-05-16	0.30	2014-06-02
2014-02-20	0.29	2014-03-10
2013-11-18	0.28	2013-12-03
2013-08-16	0.27	2013-09-03
2013-05-16	0.27	2013-06-03
2013-02-19	0.27	2013-03-07
2012-11-13	0.20	2012-12-03
2012-08-13	0.21	2012-09-04
2012-05-17	0.20	2012-06-04
2012-02-23	0.20	2012-03-15
2011-11-09	0.17	2011-12-07
2011-08-04	0.20	2011-08-25
2011-05-19	0.20	2011-06-07
2011-02-10	0.22	2011-03-07
2010-11-08	0.17	2010-12-06
2010-08-02	0.17	2010-08-26
2010-05-10	0.16	2010-06-04
2010-02-19	0.16	2010-03-17
2009-11-06	0.13	2009-12-04
2009-08-03	0.12	2009-08-27
2009-05-08	0.12	2009-06-03
2009-02-23	0.11	2009-03-19
2008-11-07	0.09	2008-12-05
2008-08-01	0.10	2008-08-27
2008-05-13	0.11	2008-06-05
2008-02-15	0.10	2008-03-13
2007-11-02	0.08	2007-11-28
2007-08-10	0.08	2007-09-06
2007-05-10	0.08	2007-06-05
2007-02-16	0.08	2007-03-15
2006-11-10	0.07	2006-12-06
2006-08-11	0.06	2006-09-08
2006-05-12	0.06	2006-06-07
2006-03-06	0.06	2006-03-30
2005-11-10	0.05	2005-12-07
2005-08-11	0.05	2005-09-07
2005-05-05	0.06	2005-06-01
2005-02-17	0.06	2005-03-17
2004-11-09	0.04	2004-12-06
2004-08-09	0.04	2004-09-07
2004-05-10	0.15	2004-06-07
2004-02-20	0.08	2004-03-22
2003-11-13	0.06	2003-12-12
2003-08-08	0.06	2003-09-08
2003-05-08	0.06	2003-06-06
2003-02-24	0.05	2003-03-24
2002-11-07	0.07	2002-12-06
2002-08-19	0.07	2002-09-16
2002-05-20	0.07	2002-06-17
2002-02-15	0.08	2002-03-18
2001-11-16	0.05	2001-12-17
2001-08-20	0.05	2001-09-17
2001-05-17	0.05	2001-06-15
2001-03-08	0.05	2001-04-06
2000-11-16	0.04	2000-12-15
2000-08-24	0.04	2000-09-21
2000-05-19	0.04	2000-06-19
2000-02-17	0.08	2000-03-27
1999-11-04	0.05	1999-11-30
1999-08-18	0.05	1999-09-13
1999-05-21	0.05	1999-06-15
1999-03-08	0.05	1999-03-30
1998-11-20	0.05	1998-12-11
1998-08-21	0.06	1998-09-11
1998-05-21	0.06	1998-06-22
1998-03-12	0.06	1998-03-31
1997-11-20	0.07	1997-12-09
1997-08-25	0.07	1997-09-11
1997-05-23	0.07	1997-06-12
1997-03-07	0.07	1997-03-26
1996-11-20	0.05	1996-12-09
1996-08-26	0.05	1996-09-12
1996-05-23	0.05	1996-06-12
1996-03-07	0.05	1996-03-26
1995-11-20	0.05	1995-12-07
1995-08-14	0.05	1995-08-30
1995-05-17	0.05	1995-06-07
1995-03-07	0.05	1995-04-04
1994-11-15	0.05	1994-12-13
1994-08-09	0.05	1994-09-12
1994-05-18	0.05	1994-06-21
1994-03-08	0.05	1994-04-05
1993-11-17	0.04	1994-01-03
1993-08-17	0.04	1993-09-14
1993-05-18	0.03	1993-06-21
1993-04-07	0.06	1993-05-05
1992-11-17	0.04	1992-12-21
1992-08-18	0.04	1992-09-21
1991-11-20	0.04	1991-12-19
1991-08-21	0.04	1991-09-19
1991-05-20	0.04	1991-07-20
1991-03-05	0.04	1991-03-28
1990-11-20	0.04	1990-12-20
1990-08-17	0.04	1990-09-17
1989-05-22	0.04	1989-06-19
1988-12-06	0.04	1988-12-30
1988-09-08	0.04	1988-10-05
1988-06-10	0.03	1988-07-20
1988-04-11	0.03	1988-05-16
1988-02-08	0.03	1988-03-10
1987-10-23	0.03	1987-11-19
1987-07-09	0.04	1987-08-05
1987-06-22	0.03	1987-07-14
1987-02-23	0.03	1987-03-26
1985-09-23	0.02	1985-10-21
1985-06-17	0.02	1985-07-15
1984-01-27	0.02	1984-02-29
1982-08-16	0.40	1982-09-13
1982-08-10	0.06	1982-09-13

公司名称	梯瓦制药
行业分类	制药
业务描述	Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

梯瓦制药 TEVA 深 沪

18.05

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

梯瓦制药 TEVA 深沪